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Abstract 
Background: Current diagnostic blood tests for prostate cancer (PCa) are unreliable for the early stage disease, 
resulting in numerous unnecessary prostate biopsies in men with benign disease and false reassurance of negative 
biopsies in men with PCa. Predicting the risk of PCa is pivotal for making an informed decision on treatment options 
as the 5-year survival rate in the low-risk group is more than 95% and most men would benefit from surveillance 
rather than active treatment. Three-dimensional genome architecture and chromosome structures undergo early 
changes during tumourigenesis both in tumour and in circulating cells and can serve as a disease biomarker.
Methods: In this prospective study we screened whole blood of newly diagnosed, treatment naïve PCa patients 
(n = 140) and cancer-free controls (n = 96) for the presence of 14,241 chromosomal loops in the loci of 425 genes.
Results: We have detected specific chromosome conformation changes in the loci of ETS1, MAP3K14, SLC22A3 and 
CASP2 genes in peripheral blood from PCa patients yielding PCa detection with 80% sensitivity and 80% specificity. 
Further analysis between PCa risk groups yielded prognostic validation sets consisting of HSD3B2, VEGFC, APAF1, BMP6, 
ERG, MSR1, MUC1, ACAT1 and DAPK1 genes that achieved 80% sensitivity and 93% specificity stratifying high-risk cat-
egory 3 vs low risk category 1 and 84% sensitivity and 89% specificity stratifying high risk category 3 vs intermediate 
risk category 2 disease.
Conclusions: Our results demonstrate specific chromosome conformations in the blood of PCa patients that allow 
PCa diagnosis and risk stratification with high sensitivity and specificity.
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Background
In the Western world prostate cancer (PCa) is now the 
most commonly diagnosed non-cutaneous cancer in men 
and is the second leading cause of cancer-related death 
[1, 2]. Many men as young as 30 show evidence of his-
tological PCa [3, 4], most of which is microscopic and 
some may not manifest clinically. For the diagnosis and 
prognosis, prostate specific antigen (PSA), magnetic res-
onance imaging (MRI), an invasive needle biopsy, Glea-
son score and disease stage are used [5, 6].
The only available blood test for PCa in widespread 
clinical use involves measuring circulating levels of PSA 
(at 4 ng/ml has 21% sensitivity and 93% specificity, PCa 
prevention trial) [7], however, the prostate size, benign 
prostatic hyperplasia and prostatitis may also increase 
PSA levels. PSA cut off levels are age-specific. Ameri-
can urological association thresholds (ng/ml) are as fol-
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70–79 = 6.5. In the UK, in men aged 50–69 years, a read-
ing of 3.0  ng/ml or higher leads to urgent referral for 
further investigation. However, men with low PSA can 
have cancer. In a large US study, 2950 men (age range, 
62 to 91  years) with PSA < 4.0  ng/ml underwent biopsy. 
PCa was diagnosed in 449 (15.2%); 67 of these 449 can-
cers (14.9%) had a Gleason score of 7 or higher [8]. Fur-
thermore, younger patients with Gleason 8–10 cancer 
and PSA levels of < 4.0  ng/ml have more aggressive dis-
ease than those with PSA levels of 4 to 9.9 ng/ml [9]. In 
early PCa, PSA testing is not specific enough to differ-
entiate between early-stage invasive cancers and latent, 
non-lethal tumours that might otherwise have remained 
asymptomatic during a man’s lifetime. In advanced PCa, 
PSA kinetics are used as a clinical surrogate endpoint for 
outcome. However, while they do give a general progno-
sis they lack specificity for the individual [10]. A number 
of more specific blood tests are emerging for PCa detec-
tion including 4  K blood test (AUC 0.8) and PHI blood 
test (90% sensitivity, 17% specificity) [11]. Both PHI and 
4 K tests have a proposed prognostic value [12], however, 
its utility is limited [13] and it is currently not widely used 
in clinical practice. PSA levels, clinical disease stage and 
Gleason score are used to establish the severity of PCa 
and stratify patients to risk groups [13]. To date, there is 
no prognostic blood test available that allows differentia-
tion between low- and high-risk PCa.
Genome-wide association studies (GWAS) have iden-
tified more than 100 PCa susceptibility loci, explaining 
∼30% of the familial risk for this disease [14]. However, 
most of PCas are not familial and are linked to unidenti-
fied multiple somatic mutations. These include mutations 
in p53 (up to 64% of tumours), p21 (up to 55%), p73 and 
MMAC1/PTEN tumour suppressor genes [15], as well 
as alterations in 25 PCa susceptibility loci [16], but these 
mutations do not explain all the observed effects on gene 
regulation. Indeed, one interesting observation that arose 
from GWAS, was that most of the loci within the genome 
that confer risk to diseases including cancer are located 
outside of known protein-coding regions [17].
Epigenetic modifications play an important role in 
PCa progression [18, 19]. Aberrant DNA methylation 
(hypo- and hypermethylation) is the best-characterized 
cancer-related epigenetic alteration in PCa [20, 21]. His-
tone modifications also contribute to PCa progression 
[22, 23]. We have previously found that in human cells 
epigenetic mechanisms involving dynamic and multi-
layered chromosomal loop interactions are powerful 
regulators of gene expression [24]. Chromosome confor-
mation capture (3C) technologies allow these signatures 
to be recorded and have gained considerable attention 
for disease diagnosis [25–28]. Prostate tumours have 
been shown to undergo long-range epigenetic alterations 
in 3-dimension chromosome conformations and dis-
tinct epigenetic signatures were found in circulating 
DNA from PCa patients [29]. Another study identified 
a strong association of single nucleotide polymorphism 
rs11672691 at 19q13 with clinical features indicative of 
aggressive PCa. Mechanistically, this locus resides in an 
enhancer element and alters the binding site of HOXA2, 
a novel oncogenic transcription factor [30].
We have developed a novel epigenetic assay, as a next 
generation of the 3C technique [31]. EpiSwitch™ technol-
ogy employs 3C technique and algorithmic-based analy-
sis to identify a panel of epigenetic differences capable of 
distinguishing between cancer-free controls and diseased 
tissue samples. It detects epigenetic regulatory signature 
changes in the higher order structures of human chromo-
somes at the loci implicated in the onset and progression 
of the disease. It offers highly effective means of screen-
ing; early detection; monitoring and prognostic analysis 
of major diseases associated with aberrant gene expres-
sion [24]. One of the main advantages of using 3C-based 
chromatin interactions as biomarkers is that DNA cross-
linking is relatively stable, and following proximity liga-
tion, give rise to a stable DNA product (Fig. 1) [32]. Using 
EpiSwitch™ technology, we have shown the presence of 
melanoma-specific chromatin conformations in periph-
eral blood mononuclear cells (PBMCs) and primary 
tumours of melanoma patients [33, 34]. Fractionation 
studies showed that the detected signature comes from 
lymphocytes and not circulating tumour cells [33, 34]. 
The concentration of circulating tumour cells in circula-
tion is too low to allow detection of chromosomal con-
formations, while circulating free DNA does not retain 
3D conformations [33, 34]. In this study, we used the 
EpiSwitch™ assay to screen for, define and evaluate spe-
cific chromosome conformations in the blood of PCa 
patients and to identify loci with potential to act as diag-
nostic and prognostic markers.
Methods
Patient population
A total of 140 PCa patients and 96 cancer-free controls 
were recruited, in two cohorts. Cohort 1: men with 
(n = 105) or without (n = 77) PCa diagnosis attend-
ing urology clinic at Imperial College Healthcare NHS 
Trust were prospectively recruited from October 2010 
through September 2013. Cohort 2: Patients’ samples 
(19 cancer-free controls and 35 PCa) obtained from 
Janssen (USA). Upon recruitment, a single blood sam-
ple (5  ml) was collected from PCa patients using the 
current practice for needle and blood collection meth-
ods into the BD  Vacutainer® plastic EDTA tubes. Blood 
samples were passively frozen and stored at − 80  °C 
until processed. Prostate tumour samples were obtained 
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from previously recruited patients (n = 5) that subse-
quently underwent radical prostatectomy at Imperial 
College Healthcare NHS Trust. Patient clinical char-
acteristics are shown in Additional file 1: Table S1. The 
primary endpoint of this study was to detect changes 
in chromosomal conformations in PBMCs from PCa 
patients in comparison to cancer-free controls. There-
fore, all treatment naïve PCa patients were eligible for 
this study irrespective of grade, stage and PSA levels. 
Patients that had previous chemotherapy or patients 
with other cancers were excluded from this study. 
PCa diagnosis was established as per clinical routine 
and patients were assigned to appropriate treatment. 
For prognostic study (secondary endpoint), patients 
were stratified according to the relevant National 
Comprehensive Cancer Network (NCCN) risk groups 
(Additional file  1: Table  S2). No follow up study was 
conducted. All patients who participated in the trial 
have given informed consent. The study was approved 
by the local ethics committee (Imperial College NHS 
Trust REF 07/MRE09/54). All procedures and protocols 
were performed in accordance with the relevant guide-
lines and regulations. Based on the preliminary findings 
in melanoma [33, 34], an a priori power analysis was 
performed using the pwr.t.test function in the R pack-
age pwd.
Stepwise diagnostic and prognostic biomarker discovery 
process using EpiSwitch™ technology and data analysis
EpiSwitch™ technology platform (Oxford Biodynamics, 
Oxford, UK) pairs high resolution 3C results with regres-
sion analysis and a machine learning algorithm to develop 
disease classifications [33–36]. To select epigenetic bio-
markers that can diagnose cancers, samples from patients 
suffering from cancer, in comparison to cancer-free con-
trol samples were screened for statistically significant 
differences in conditional and stable profiles of genome 
architecture (Fig. 1). All the samples used for the nested 
polymerase chain reaction (PCR) diagnostic and prog-
nostic biomarker discovery were processed as per the 
manufacturer’s instructions using the proprietary EpiS-
witch™ reagents and standard protocols (the standard 
protocol for nested PCR is Work Instruction 52 (WI52) 
and for real-time quantitative PCR (qPCR) is WI82 
[36]). The samples for the development of the qPCR pro-
cess were processed using the EpiSwitch™ reagents and 
Fig. 1 Chromosomal loops structure and conformation assay. a Chromosomal loop contains the enhancer region that increases target gene 
promoter activity. b During cancer progression there is increased looping in some tumour-related genes leading to abnormal gene expression. 
c Chromosome conformation assay: DNA is crosslinked, digested, ligated and new sequences (in places where loops were) are predicted using 
relevance machine vector. Loops presence is then detected using DNA microarray. Resulting markers are analysed using multivariate analysis 
yielding specific epigenetic signatures for selected patient cohorts
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protocols as described previously [36]. Briefly, 50  µl of 
whole blood was suspended in 450 µl PBS, formaldehyde 
containing solution was added and the mixture incubated 
at room temperature for 15 min to fix the samples. Gly-
cine solution was added to bind any unreacted formalde-
hyde and quench the reaction. Cell membrane lysis was 
performed, and the intact nuclei purified using a density 
cushion centrifugation. TaqI restriction enzyme diges-
tion (Fermentas FastDigest™ TaqI kit) was performed 
and proximity ligation with T4 DNA ligase (Takara T4 
Ligase kit) was used to capture the inter/intra chromatin 
associations as chromosome conformation signatures. 
Proteinase K (Sigma) was added to the libraries to digest 
the constraining protein content of the samples and allow 
for greater accessibility in the PCR. The Proteinase K was 
denatured, and cross-links partially reversed at 90  °C. 
The protocols were repeated to produce the required vol-
ume of library for nested PCR investigation. The same 
process was applied to the matched tissue samples with 
the addition of an initial incubation in 0.125% (v/v) Colla-
genase (Sigma) for 37 °C with gentle agitation for 30 min 
until the tissue was suspended. The freed cells were pel-
leted by centrifugation at 800g for 5 min and the super-
natant removed before being resuspended in 500 µl PBS 
and subjected to the same protocol as described previ-
ously [37]. In short, the assay was performed on a whole 
blood sample by first fixing chromatin with formalde-
hyde to capture intrachromatin associations, as described 
before [37]. The fixed chromatin was then digested into 
fragments with TaqI restriction enzyme, and the DNA 
strands were joined favouring cross-linked fragments. 
The cross-links were reversed and PCR performed using 
the primers previously established by the EpiSwitch™ 
software (Fig. 1).
The version 2 EpiSwitch™ reagents and protocols were 
used to generate the libraries for the qPCR translation 
stage. These follow the protocol as described previously 
[37] with an additional detergent-based step between 
the density cushion centrifugation and TaqI restriction 
to increase enzyme accessibility and restriction rates. In 
addition, the Proteinase K treatment was replaced with 
the use of the  QIAmp® DNA FFPE Tissue Kit (Qiagen), 
starting at the step of resuspension of sample in ATL 
buffer.
EpiSwitch™ was used on blood samples in a three-
step process to identify, evaluate, and validate sta-
tistically significant differences in chromosomal 
conformations between PCa patients and cancer-free 
controls (Fig. 2). For the first step, sequences from 425 
manually curated PCa-related genes (obtained from the 
public databases (www.ensem bl.org)) were used as tem-
plates for this computational probabilistic identification 
of regulatory signals involved in chromatin interaction 
(Additional file  1: Table  S3). A customized CGH Agi-
lent microarray (8 × 60 k) platform was designed to test 
technical and biological repeats for 14,241 potential 
chromosome conformations across 425 genetic loci. 
Eight PCa and eight cancer-free control samples were 
competitively hybridized to the array, and differen-
tial presence or absence of each chromosome confor-
mation was defined by LIMMA linear modelling with 
empirical Bayes moderation of the standard errors, 
subsequent abundance filtering and cluster analysis. 
This initially revealed 60 chromosomal interactions 
with the ability to best discriminate PCa patients from 
cancer-free controls (Fig. 2). For the second evaluation 
stage, the 60 chromosomal interactions were translated 
into EpiSwitch™ PCR based-detection assays. Nested 
PCR primers were designed for the 60 chromosomal 
interactions and these tested using a pooled PCa and 
a pooled cancer-free control, to ascertain if they pro-
duced the expected PCR product. Of these 60 primer 
combinations, 7 failed to produce PCR products and 
were subsequently dropped from further investigation. 
The 53 successful primer combinations were screened 
on PCa and cancer-free controls (n = 6 in each group). 
Feature reduction of the 53 PCR was performed using 
an univariant statistical approach (Fishers Exact test), 
this analysis identified 15 nested PCR markers with the 
most statistical discernibility between PCa and cancer-
free controls.
The known sample cohort used to identify the 15 mark-
ers was expanded to include 49 samples (PCa n = 24, 
cancer-free controls n = 25) to provide better statistical 
power for marker selection. With the expanded cohort 
univariate (Fishers Exact test) and multivariant (GLM-
NET, penalized logistic regression, alpha 1 (lasso) and 
lambda 0.01) statistical approaches were used to further 
identify markers with the greatest statistical discernibil-
ity. GLMNET was used in combination with permuta-
tion, where the cohort was split 500 times randomly into 
a training (0.667) and test (0.333). A GLMNET model is 
developed for each data split (500) and the markers used 
in the model are given a vote, the frequency of use of the 
marker is tallied, markers used in all data splits would 
get be voted 500 times. This resampling methodology 
counters false positives in terms of marker selection. In 
combination with the univariate test for independence 
(Fishers Exact test), the final model identified was made 
up of a five-marker signature (Table 1). Principal compo-
nent analysis was also used to determine group variance 
and to identify potential outlier samples. The 49 known 
samples used for marker reduction were used to cre-
ate a logistic model classifier with five-fold cross valida-
tion. The five markers were further statistically assessed 
using 500 randomised classifiers, 250 logistic model and 
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250 naïve bayes classifiers with data resampling in each 
iteration.
For the last step, to further validate the chromosome 
conformation signature used to inform PCa diagnosis, 
the training sample cohort size was expanded to 95 PCa 
and 96 cancer-free control samples. The five-marker set 
was tested on a blinded, independent (n = 20) cohort of 
blood samples (Additional file  1: Table  S4). The results 
were analysed using Bayesian Logistic modelling, p-value 
null hypothesis (Pr(N|z|) analysis, Fisher-Exact P test and 
Glmnet.
Data analysis and presentation were performed in 
accordance with CONSORT recommendations. All 
measurements were performed in a blinded manner. 
STARD criteria have been used to validate the analytical 
procedures. A similar stepwise approach was followed 
for the identification of prognostic markers. A subset of 
prognostic markers was translated from the nested PCR 
format to qPCR assays with hydrolysable probes, to the 
industry standards of MIQE-compliant qPCR. The alter-
native qPCR format assays were validated on a subset of 
the prognostic sample cohort.
Fig. 2 Three-step approach to identify, evaluate, and validate diagnostic and prognostic biomarkers for prostate cancer (PCa)
Table 1 Five-marker signature used for the diagnosis of prostate cancer (PCa)
Markers Gene symbol Gene name P value
PCa.57.59 ETS1 ETS proto-oncogene 1, transcription factor 0.11
PCa.81.83 MAP3K14 Mitogen-activated protein kinase kinase kinase 14 0.11
PCa.73.75 SLC22A3 Solute carrier family 22 member 3 0.107
PCa.77.79 SLC22A3 Solute carrier family 22 member 3 0.005
PCa.189.191 CASP2 Caspase 2 0.137
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Nested polymerase chain reaction (PCR)
Sequence specific oligonucleotides were designed 
around the chosen sites for screening potential markers 
by nested PCR using Primer3. All PCR amplified sam-
ples were visualized by electrophoresis in the LabChip 
GX, using the LabChip DNA 1  K Version2 kit (Perkin 
Elmer, Beaconsfield, UK) and internal DNA marker 
was loaded on the DNA chip according to the manu-
facturer’s protocol using fluorescent dyes. Fluorescence 
was detected by laser and electropherogram read-outs 
translated into a simulated band on gel picture using 
the instrument software. The threshold we set for a 
band to be deemed positive was 30 fluorescence units 
and above.
Real‑time quantitative PCR (qPCR) assay development
Both the inner and outer primer combinations of prim-
ers for markers identified in the nested PCR investiga-
tion were subjected to a temperature gradient PCR to 
identify the optimum annealing temperature using 
EpiSwitch™ libraries as the template inputs. The PCR 
products were detected using SYBR green amplification 
and melt curves. All PCR amplified samples were visu-
alised by electrophoresis. The PCR products were gel 
purified, sequenced and mapped to the human refer-
ence genome to validate the 3C products. The sequence 
verified PCR products were used to create standards for 
absolute quantification starting at a  106 copies standard. 
Hydrolysis probes were designed across the restriction/
ligation junction of the 3C products to produce specific 
detection of the 3C products of interest. The hydrolysis 
probe detection was again subjected to a temperature 
gradient PCR to identify the optimum annealing/exten-
sion temperature for the specific detection of the PCR 
products. The generated  106 copy standard was used as 
the positive control alongside standard EpiSwitch tem-
plate and no template controls.
Detection of similar epigenetic markers in blood 
and matching primary prostate tumours
Primary tumour samples were obtained from biopsies 
of selected patients from Imperial College Healthcare 
NHS Trust cohort (n = 5). The pulverized tissue sam-
ples were incubated in 0.125% collagenase at 37  °C 
with gentle agitation for 30  min. The resuspended 
cells (250  µl) were then centrifuged at 800g for 5  min 
at room temperature in a fixed arm centrifuge, super-
natant removed, and the pellets resuspended in phos-
phate-buffered saline. Primary tumours and matching 
blood samples were analysed for the presence of the 
six-marker set for categories 3 vs 1 and 3 vs 2 at a fixed 
range of assay sensitivity (dilution factor 1:2). When 
matching PCR bands of the correct size were detected, 
a score of 1 was assigned, detection of no band was 
assigned a score of 0 (Table 2).
Results
Identification of the diagnostic markers
We have applied a stepwise diagnostic biomarker discov-
ery process using EpiSwitch™ technology as described 
in methods. A customized CGH Agilent microarray 
(8 × 60  k) platform was designed to test technical and 
biological repeats for 14,241 potential chromosome 
conformations across 425 genetic loci (Additional file 1: 
Table S3) in eight PCa and eight cancer-free control sam-
ples (Figs.  1, 2). The presence or absence of each locus 
was defined by LIMMA linear modelling, subsequent 
binary filtering and cluster analysis. In the second evalu-
ation stage, nested PCR was used for the 53 selected bio-
markers further reducing them to 15 markers and finally 
to a five-marker signature (Fig. 2). This distinct chromo-
some conformation disease signature for PCa comprised 
of chromosomal interactions in five genomic loci: ETS 
proto-oncogene 1, transcription factor (ETS1), mitogen-
activated protein kinase kinase kinase 14 (MAP3K14), 
solute carrier family 22 member 3 (SLC22A3) and cas-
pase 2 (CASP2) (Table  1). The presence of an altered 
loop in each of the genes individually (except SLC22A3) 
was not statistically significant in predicting cancer. 
Only a combination of five of them provided required 
accuracy in the logistic model (please see the Stepwise 
Data Analysis section in Methods). The genomic loca-
tions of specific chromosomal loops in ETS1, MAP3K14, 
SLC22A3 and CASP2 genes in the chromosome con-
formation signature (Table  1) were mapped on their 
relative chromosomes in Fig.  3. The two genomic sites 
that corresponded to the junction of each chromosome 
conformation signature locus for ETS1, MAP3K14, 
SLC22A3 and CASP2 genes were mapped on chromo-
some 11 from 128,260,682 to 128,537,926; chromosome 
17 from 43,303,603 to 43,432,282; chromosome 6 from 
160,744,223 to 160,944,757 and chromosome 7 from 
142,935,233 to 143,008,163, respectively, with the EpiS-
witch™ sites marked with colour (Fig.  3a). Circos plots 
of ETS1, MAP3K14, SLC22A3 and CASP2 chromosome 
conformation signature markers showing the chromo-
somal loops are depicted in Fig. 3b.
Principal component analysis for the five-markers 
was used to determine group variance and to identify 
potential outlier samples. This analysis was applied to 78 
samples containing two groups. First group, 49 known 
samples (24 PCa and 25 cancer-free controls) combined 
with a second group of 29 samples including, 24 PCa 
samples and 5 cancer-free control samples demonstrat-
ing no outliers (Fig.  4). The final training set was built 
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using 95 PCa and 96 cancer-free control samples and 
then tested on an independent blinded validation cohort 
of 20 samples (10 cancer-free controls and 10 PCa). The 
sensitivity and specificity for PCa detection using chro-
mosomal interactions in five genomic loci were 80% 
(CI 44.39% to 97.48%) and 80% (CI 44.39% to 97.48%), 
respectively (Additional file 1: Table S4).
Identification of the prognostic markers
To select epigenetic biomarkers that can stratify PCa, the 
samples from PCa patients categorised into risk group 
categories 1–3 (low (n = 42), intermediate (n = 18) and 
high (n = 25), respectively, Additional file  1: Table  S2) 
were screened for statistically significant differences in 
conditional and stable profiles of genome architecture. 
EpiSwitch™ was used on blood samples in a three-step 
process to identify, evaluate, and validate statistically 
significant differences in chromosomal conformations 
between PCa patients at different stages of the disease 
(Fig.  2). For the first step, the array used covered 425 
genetic loci, with testing probes for the total of 14,241 
potential chromosomal conformations. Patients with 
high-risk PCa category 3 were compared to low-risk 
category 1 or intermediate-risk category 2. In total, 181 
potential stratification marker leads for PCR evaluation 
were identified using enrichment statistics (Additional 
file 1: Table S5). The top 70 top markers were then taken 
to the next stage of PCR detection for further evaluation 
and stratification of high-risk category 3, vs low-risk cat-
egory 1 patient samples. The 70 markers were reduced to 
16 and finally a six-marker set for high category 3 vs low 
category 1 was established (Additional file  1: Table  S6). 
The best markers were identified using Chi-square and 
then built into a classifier on a testing set of category 1 
(n = 21) and category 3 (n = 19). An independent cohort 
of category 1 (n = 21) and category 3 (n = 6) which were 
not used for any marker reduction were then used for 
first round of blind validation. Similarly, a six-marker set 
was evaluated for high-risk category 3 vs intermediate-
risk category 2 on a testing set of category 3 and category 
2 including, 17 and 12 samples, respectively. An inde-
pendent cohort of category 2 and category 3 (n = 6 in 
each group) which were not used for any marker reduc-
tion were then used for first round of blind validation.
For the last step, to further validate the chromosome 
conformation signature used to inform PCa prognosis, 
the six-marker set for high-risk category 3 vs low-risk 
category 1 was tested on a larger, more representative 
cohort. The original blind cohort was expanded to 67 
samples, including 40 samples used in marker reduction 
(Additional file 1: Table S7). Similarly, the six-marker set 
for high-risk category 3 vs intermediate-risk category 2 
was tested on a on a larger, more representative cohort. 
The original blind cohort was expanded to 43 samples 
(Additional file 1: Table S8).
A six-marker set for category 3 vs category 1 was estab-
lished. This set contained bone morphogenetic protein 
6 (BMP6), ETS transcription factor ERG (ERG), mac-
rophage scavenger receptor 1 (MSR1), mucin 1 (MUC1), 
acetyl-CoA acetyltransferase 1 (ACAT1) and death-asso-
ciated protein kinase 1 (DAPK1) genes (Additional file 1: 
Table  S6). Six-biomarkers were identified for high-risk 
category 3 vs intermediate-risk category 2, including 
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and ster-
oid delta-isomerase 2 (HSD3B2), vascular endothelial 
growth factor C (VEGFC), apoptotic peptidase activating 
factor 1 (APAF1), MUC1, ACAT1 and DAPK1. Notably, 
the last three-biomarkers (MUC1, ACAT1 and DAPK1) 
were common between categories 1 vs 3 and 3 vs 2 (Addi-
tional file 1: Table S6). Stratification of high-risk category 
3 vs low-risk category 1 PCa using chromosomal inter-
actions in six genomic loci showed sensitivity of 80% 
(CI 59.30% to 93.17%) and specificity of 93% (CI 80.52% 
to 98.50%) in the blind cohort of 67 samples (Additional 
file 1: Table S7). Similarly, the six-marker set for high-risk 
category 3 vs intermediate-risk category 2 was tested on 
a on a larger, more representative cohort of 43 samples 
demonstrating sensitivity of 84% (CI 63.92% to 95.46%), 
and specificity of 89% (CI 65.29% to 98.62%) (Additional 
file 1: Table S8).
Detection of similar epigenetic markers in blood 
and matching primary prostate tumours
Using five matching peripheral blood and primary 
tumour samples, we have compared the epigenetic 
markers identified in peripheral circulation (Addi-
tional file 1: Table S6) to the tumour tissue. Our results 
showed that a number of deregulation markers detected 
in the blood as part of stratifying signatures for cat-
egory 1 vs 3 and category 2 vs 3 could be detected in 
the tumour tissue (Table  2). This demonstrates that 
the chromosome interactions that can be detected 
(See figure on next page.)
Fig. 3 Graphical representation of the genomic co-ordinates of the ETS1, MAP3K14, SLC22A3 and CASP2 chromosome conformation signature 
markers associated with PCa. a The Ensembl browser view of the ETS1, MAP3K14, SLC22A3 and CASP2 genes on chromosomes 11, 17, 6 and 7 with 
the EpiSwitch™ sites marked with green, pink, blue and red symbols, respectively. b Circos plots of ETS1 (green) MAP3K14 (pink), SLC22A3 (blue) 
and CASP2 (red) chromosome conformation signature markers showing the chromosomal loop
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systemically could be detected under same conditions 
in the primary site of tumourigenesis.
Real‑time quantitative PCR (qPCR) translation
The 16 statistically significant markers identified in the 
prognostic marker screen were translated to real-time 
qPCR assays. Due to the nature of 3C templates the 
sequence available for suitable primer and probe design 
for qPCR is constrained. This led to 6 of the markers 
failing to be translated to the qPCR assay. The assays 
were further assessed over the nested PCR assays by 
screening a 40-sample subset of the prognostic sample 
cohort. The cohort consisted of 10 cancer-free controls, 
10 category 1, 10 category 2 and 10 category 3 samples. 
A new classifier was produced using the qPCR data and 
tested with resampling for the ability to distinguish 
between the cancer-free controls and PCa based on 6 
markers, demonstrating average sensitivity of an 91% 
and specificity of 89.3% based on 500 randomisations 
for cross validation and a 66/34% train/test split.
Discussion
Timely diagnosis of PCa is crucial to reducing mortality. 
The European randomised study of screening for PCa has 
shown significant reduction in PCa mortality in men who 
underwent routine PSA screening [38, 39]. This notion 
was, however, not supported by the results of prostate, 
lung, colorectal, and ovarian (PLCO) cancer screening 
trial in the USA [40]. Total population screening leads to 
overdiagnosis of clinically insignificant disease and new 
less invasive tests capable of discriminating low- from 
high-risk disease are urgently required.
Our epigenetic analysis approach provides a poten-
tially powerful means to address this need. The binary 
nature of the test (the chromosomal loop is either present 
or not) and the enormous combinatorial power (> 1010 
combinations are possible with ~ 50,000 loops screened) 
may allow creating signatures that accurately fit clini-
cally well-defined criteria. In PCa that would be discern-
ing low-risk vs high-risk disease or identifying small but 
aggressive tumours and determining most appropriate 
therapeutic options. In addition, epigenetic changes are 
Fig. 4 Principal component analysis for the five-markers applied to 78 samples containing two groups. First group, 49 known samples (24 PCa and 
25 cancer-free controls (Cntrl)) combined with a second group of 29 samples including, 24 PCa samples and 5 healthy Cntrl samples. PCa samples in 
green and cancer-free Cntrl samples in red
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known to manifest early in tumourigenesis, making them 
useful for both diagnosis and prognosis [41].
In this study, we identified and validated chromosome 
conformations as distinctive biomarkers for a non-inva-
sive blood-based epigenetic signature for PCa. Our data 
demonstrate the presence of stable chromatin loops in 
the loci of ETS1, MAP3K14, SLC22A3 and CASP2 genes 
present only in PCa patients (Table 1). Validation of these 
markers in an independent set of 20 blinded samples 
showed 80% sensitivity and 80% specificity (Additional 
file 1: Table S4), which is remarkable for a PCa blood test. 
Interestingly, the expression of some of these genes has 
already been linked to cancer pathophysiology. ETS1 is a 
member of ETS transcription factor family. ETS1‐overex-
pressing prostate tumours are associated with increased 
cell migration, invasion and induction of epithelial‐to‐
mesenchymal transition [42]. MAP3K14 (also known 
as nuclear factor-kappa-beta (NF-kβ)-inducing kinase 
(NIK)) is a member of MAP3K group (or MEKK). Physi-
ologically, MAP3K14/NIK can activate noncanonical 
NF-kβ signalling and induce canonical NF-kβ signalling, 
particularly when MAP3K14/NIK is overexpressed [43]. 
A novel role for MAP3K14/NIK in regulating mitochon-
drial dynamics to promote tumour cell invasion has been 
described [44]. SLC22A3 (also known as organic cation 
transporter 3) is a member of SLC group of membrane 
transport proteins. SLC22A3 expression is associated 
with PCa progression [45]. CASP2 is a member of cas-
pase activation and recruitment domains group. Physi-
ologically, CASP2 can act as an endogenous repressor of 
autophagy [46]. Two of the identified genes (SLC22A3 
and CASP2) were previously shown to be inversely cor-
related with cancer progression [45, 47, 48]. Importantly, 
the presence of the chromatin loop can have indetermi-
nate effect on gene expression.
To screen for PCa prognostic markers we performed 
the EpiSwitch™ custom array to analyse competi-
tive hybridization of DNA from peripheral blood from 
patients with low-risk PCa (category 1) and high risk PCa 
(category 3). Six-marker set was identified for high-risk 
category 3 vs low-risk category 1, including BMP6, ERG, 
MSR1, MUC1, ACAT1 and DAPK1. Six-biomarkers were 
identified for high-risk category 3 vs intermediate-risk 
category 2, including HSD3B2, VEGFC, APAF1, MUC1, 
ACAT1 and DAPK1. Three of these biomarkers (MUC1, 
ACAT1 and DAPK1) were shared between these sets. 
Our data show high concordance between chromosomal 
conformations in the primary tumour and in the blood 
of matched PCa patients at stages 1 and 3 (Table 2). The 
prognostic significance and diagnostic value of some of 
these genes have previously been suggested [49–52]. 
BMP6 plays an important role in PCa bone metastasis 
[50]. In addition to ETS1, ERG is another member of the 
ETS family of transcription factors. Overwhelming evi-
dence, reviewed in [49], suggested that ERG is implicated 
in several processes relevant to PCa progression includ-
ing metastasis, epithelial–mesenchymal transition, epi-
genetic reprogramming, and inflammation [49]. MSR1 
may confer a moderate risk for PCa [53]. MUC1 is a 
membrane-bound glycoprotein that belongs to the mucin 
family. MUC1 high expression in advanced PCa is asso-
ciated with adverse clinicopathological tumour features 
and poor outcomes [51]. ACAT1 expression is elevated 
in high-grade and advanced PCa and acts as an indica-
tor of reduced biochemical recurrence-free survival [52]. 
DAPK1 could function either as a tumour suppressor or 
as an oncogenic molecule in different cellular context 
[54]. HSD3B2 plays a crucial role in steroid hormone 
biosynthesis and it is up-regulated in a relevant fraction 
of PCa that are characterized by an adverse tumour phe-
notype, increased androgen receptor signalling and early 
biochemical recurrence. [55]. VEGFC is a member of 
VEGF family and its increased expression is associated 
with lymph node metastasis in PCa specimens [56]. In a 
comprehensive biochemical approach, APAF1 has been 
described as the core of the apoptosome [57].
Despite the identification of these loci, the mechanism 
of cancer-related epigenetic changes in PBMCs remains 
unidentified. The interaction, however, could be detected 
systemically and under same conditions in the primary 
site of tumourigenesis (Table 2). It is therefore assumed 
that the acquired changes must be directed by an exter-
nal factor; presumably generated by the tumour cells. It 
is known that a significant proportion of chromosomal 
conformations are controlled by non-coding RNAs, 
which regulate the tumour-specific conformations [58, 
59]. Tumour cells have been shown to secrete non-coding 
RNAs that are endocytosed by neighbouring or circulat-
ing cells and may change their chromosomal conforma-
tions [59, 60], and are possible regulators in this case.
RNA detection as a biomarker remains highly challeng-
ing (low stability, background drift, continuous variable 
for statistical stratification analysis). Chromosome con-
formation signatures offer well recognized stable binary 
advantages for the biomarker targeting use [25], specifi-
cally when tested in the nuclei [31], since the circulating 
DNA present in plasma does not retain 3D conforma-
tional topological structures present in the intact cellu-
lar nuclei. It is important to mention, that looking at one 
genetic locus does not equate to looking at one marker, as 
there may be multiple chromosome conformations pre-
sent, representing parallel pathways of epigenetic regula-
tion over the locus of interest.
Other technologies for plasma-based cancer detection 
such as using plasma cell-free DNA (cfDNA) methyl-
omes [61] were recently introduced. The validity of this 
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assay was tested to identify patients with renal cell carci-
noma using urine cfDNA with area under the ROC curve 
(AUROC) of 0.86 [62]. It is worth noting that cfDNA is 
capturing post-apoptotic and necrotic passive distri-
bution of free DNA, with significant variations, while 
EpiSwitch is measuring 3D genomic profiling in intact 
cells, capturing systemic surrogate readouts, which, for 
epigenetic modalities, have been shown to contain syn-
chronized modulation at specific genetic loci concordant 
with primary sites of deregulation [63]. Systemic surro-
gate signatures at selective loci at the level of 3D genom-
ics are sustained through exosome signalling and are not 
restricted to oncology [36].
One of the key challenges in the present clinical prac-
tice of PCa diagnosis is the time it takes to make a defini-
tive diagnosis. So far, there is no single, definitive test 
for PCa. High levels of PSA will set the patient on a long 
journey of uncertainty where he will undergo a MRI 
scan followed by biopsy, if needed. Although a biopsy is 
more reliable than a PSA test, it is an invasive procedure 
at which targeting the cancer remains a significant issue. 
The five-set biomarker panel described here is based on 
a relatively inexpensive and well-established molecular 
biology technique (PCR). The samples are based on bio-
fluid, which is simple to collect and provides clinicians 
with rapidly available clinical readouts within few hours. 
This in turn, offers a substantial time and cost savings and 
aids an informative diagnostic decision with the promise 
to help fill the gap in the current protocols for assertive 
diagnosis of PCa.
Predicting the risk of PCa is pivotal for making an 
informed decision on treatment options. Five-year sur-
vival rate in the low risk group is more than 95% and 
most men would benefit from less invasive therapy. 
Currently, PCa risk stratification is based on combined 
assessment of circulating PSA, tumour grade (from 
biopsy) and tumour stage (from imaging findings). The 
ability to derive similar information using a simple blood 
test would allow significant reduction in costs and would 
speed up the diagnostic process. Of particular impor-
tance in PCa treatment is identifying the few tumours 
that initially present as low-risk, but then progress to 
high-risk. This subset would therefore benefit from a 
quicker and more-radical intervention.
This study has several limitations including smaller 
number of patients in diagnostic validation cohort, una-
vailability of other clinical indices like PHI and 4 K (which 
are not part of the standard of care in the UK) and no 
follow-up (due to double anonymity). It is worth noting 
that the aim of this study was to demonstrate the poten-
tial capability of our general method and the new para-
digm, rather than introduce a new clinical test for PCa 
that would require larger specialised studies in different 
settings. The exact mechanism of concordance between 
leukocyte 3D chromosome conformations and those in 
primary tumours remains unclear. We hypothesise that it 
is mediated by the horizontal transfer of epigenetic infor-
mation, likely through non-coding RNAs, however, dedi-
cated studies are required to investigate this further.
Conclusions
In conclusion, we have identified subsets of chromosomal 
conformations in patients’ PBMCs that are strongly 
indicative of PCa presence and prognosis. These signa-
tures have significant potential for the development of 
quick diagnostic and prognostic blood tests for PCa and 
significantly exceed the specificity of the currently used 
PSA test.
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